Evogene (EVGN) Stock Price, Quote, News & History

Evogene Ltd (EVGN) Stock Price, Quote, News & History

EVGNNASDAQ

Trade with Public

$0.7806

-0.0032-0.41%

At close: Apr 6, 5:00 PM EST

$0.8490

0.06848.76%

After Hours: 9:24 AM EST

Key Statistics

Open

$0.78

Volume / Avg.

99.90K / 466.86K

Day Range

$0.77 - $0.83

52 Wk Range

0.72 - 2.42

Market Cap

$8.40M

P/E Ratio

Dividend Yield

Exchange

NASDAQ

RSI

Short Interest

2.45%

Days to Cover

1.28

Recent Evogene Ltd News

Evogene Stock Soars After ICL Deal To Acquire Lavie Bio, MicroBoost AI

Evogene's stock surged on news of ICL's acquisition of Lavie Bio's operations, strengthening ICL's position in ag-biologicals.

Akanksha Bakshi

Israeli Company Reports Record 2023 Revenue, Wants To Transition Cannabis Operations To 'Third Party'

Evogene Ltd. released its fourth-quarter and full-year 2023 financial results, showing a 237% revenue increase for the year. Despite a 12% revenue decrease in Q4, the Israeli cannabis company reported $5.6 million in total revenue for the year. CEO Ofer Haviv highlighted the company's successful collaborations with industry leaders like Corteva, ICL, and Syngenta, contributing to revenue growth. In Q4, gross profit decreased to $180,000, but net financing income rose to $287,000. Total operating expenses increased to $7.8 million, leading to a net loss of $7.3 million. For the full year, gross profit reached $3.9 million, and net financing income was approximately $521,000. Evogene also secured partnerships with Verb Biotics and Colors Farm, along with receiving a €1.2 million EU grant for its Ag-Seed Division's research and development efforts.

Jelena Martinovic

Israeli Cannabis Company Reports Strong Q3 Despite Geopolitical Challenges

Evogene reports a strong Q3 with $3.8M revenue and significant gross profit growth, showcasing resilience and innovation in cannabis tech.

Patricio Liddle

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-13.50M

Investing Cash Flow (TTM)

17.74M

Financing Cash Flow (TTM)

-6.60M

Free Cash Flow (TTM)

-13.64M

Capital Expenditure (TTM)

-135.00K

Net Change in Cash (TTM)

-2.37M

Analyst Rating and Forecast

4.0

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

-$2.93M

PE Ratio (TTM)

PE Ratio (FWD)

PEG Ratio (TTM)

PS Ratio (TTM)

1.60

PB Ratio (TTM)

Earnings Yield % (TTM)

-216.89%

Earnings Yield % (FWD)

-140.34%

EV / EBITDA (TTM)

Price / EBITDA (TTM)

Price / Free Cash Flow (TTM)

Book Value / Share

-$0.01

Company Debt

Total Debt

LT Debt

LT Debt Issuance (TTM)

LT Debt Repayment (TTM)

-$526.00K

Total Cash

$12.96M

Debt to Equity

Issuance of Debt (TTM)

-$526.00K

Repayment of Debt (TTM)

-$526.00K

Key Statistics

Open

$0.78

Volume / Avg.

99.90K / 466.86K

Day Range

$0.77 - $0.83

52 Wk Range

0.72 - 2.42

Market Cap

$8.40M

P/E Ratio

Dividend Yield

Exchange

NASDAQ

RSI

Short Interest

2.45%

Days to Cover

1.28

About

Sector

Health Care

Industry

Biotechnology

Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computation...

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

How do I buy Evogene (EVGN) stock?

You can purchase shares of Evogene (NASDAQ:EVGN) through any online brokerage.

View our list of the best stock brokerages

Who are Evogene (EVGN) competitors?

Other companies in Evogene’s space includes: Acurx Pharmaceuticals Inc (NASDAQ:ACXP), Imunon Inc (NASDAQ:IMNN), Cellectar Biosciences Inc (NASDAQ:CLRB), Lunai Bioworks Inc (NASDAQ:LNAI) and Can Fite Biopharma Ltd (AMEX:CANF).

What is the forecast, or price target, for Evogene (EVGN) stock?

Evogene has a consensus price target of $3.78.

What is the current price for Evogene (EVGN)?

The stock price for Evogene (NASDAQ: EVGN) is $0.849 last updated April 6, 2026 at 9:24 AM EDT.

Does Evogene (EVGN) pay a dividend?

There are no upcoming dividends for Evogene.

When is Evogene (NASDAQ:EVGN) reporting earnings?

Evogene does not have any upcoming earnings scheduled.

Is Evogene (EVGN) going to split?

There is no upcoming split for Evogene.

What sector and industry does Evogene (EVGN) operate in?

Evogene is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

People Also Watch

Acurx Pharmaceuticals Inc

Cellectar Biosciences Inc

Can Fite Biopharma Ltd

AMEX:CANF

$3.11

1.63%

Bolt Biotherapeutics Inc

NASDAQ:BOLT

$4.00

-18.86%

BioRestorative Therapies Inc

NASDAQ:BRTX

$0.25

0.40%

AlphaTON Capital Corp

NASDAQ:ATON

$0.33

0.59%

Key Statistics

Open

$0.78

Volume / Avg.

99.90K / 466.86K

Day Range

$0.77 - $0.83

52 Wk Range

0.72 - 2.42

Market Cap

$8.40M

P/E Ratio

Dividend Yield

Exchange

NASDAQ

RSI

Short Interest

2.45%

Days to Cover

1.28

Recent Evogene Ltd News

Evogene Stock Soars After ICL Deal To Acquire Lavie Bio, MicroBoost AI

Evogene's stock surged on news of ICL's acquisition of Lavie Bio's operations, strengthening ICL's position in ag-biologicals.

Akanksha Bakshi

Israeli Company Reports Record 2023 Revenue, Wants To Transition Cannabis Operations To 'Third Party'

Jelena Martinovic

Israeli Cannabis Company Reports Strong Q3 Despite Geopolitical Challenges

Evogene reports a strong Q3 with $3.8M revenue and significant gross profit growth, showcasing resilience and innovation in cannabis tech.

Patricio Liddle

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-13.50M

Investing Cash Flow (TTM)

17.74M

Financing Cash Flow (TTM)

-6.60M

Free Cash Flow (TTM)

-13.64M

Capital Expenditure (TTM)

-135.00K

Net Change in Cash (TTM)

-2.37M

Analyst Rating and Forecast

4.0

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

-$2.93M

PE Ratio (TTM)

PE Ratio (FWD)

PEG Ratio (TTM)

PS Ratio (TTM)

1.60

PB Ratio (TTM)

Earnings Yield % (TTM)

-216.89%

Earnings Yield % (FWD)

-140.34%

EV / EBITDA (TTM)

Price / EBITDA (TTM)

Price / Free Cash Flow (TTM)

Book Value / Share

-$0.01

Company Debt

Total Debt

LT Debt

LT Debt Issuance (TTM)

LT Debt Repayment (TTM)

-$526.00K

Total Cash

$12.96M

Debt to Equity

Issuance of Debt (TTM)

-$526.00K

Repayment of Debt (TTM)

-$526.00K

Key Statistics

Open

$0.78

Volume / Avg.

99.90K / 466.86K

Day Range

$0.77 - $0.83

52 Wk Range

0.72 - 2.42

Market Cap

$8.40M

P/E Ratio

Dividend Yield

Exchange

NASDAQ

RSI

Short Interest

2.45%

Days to Cover

1.28

About

Sector

Health Care

Industry

Biotechnology

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry